A Transcriptomic Fingerprint for Parkinson's Disease Found in Patients with Chronic Inflammatory Response Syndrome: Implications for Diagnosis, Treatment and Prevention

Main Article Content

R Shoemaker J Ryan A Heyman E Dorninger S McMahon D Lark

Abstract

Parkinson's Disease (PD) is the second most common neurodegenerative disease worldwide, characterized by a movement disorder that includes tremors, micrographia, difficulty initiating and stopping movement, stiffness, raspy voice, constipation, fatigue, anosmia, musculoskeletal pain and loss of balance resulting in significant disability, risk for infection and substantial need for care of activities of daily living. Many people with PD also develop dementia. The onset of illness usually begins during the 6th decade of life. Neuropathology of PD is characterized by progressive loss of dopaminergic neurons of the substantia nigra marked by intracellular accumulation of α-synuclein in the form of Lewy bodies and Lewy neurites. While dopamine-promoting medications are the mainstay of treatment to reduce symptoms, there is no cure. The leading cause of death is pneumonia, and an average life expectancy is 14.5 years.


We recently reported abnormalities in cytoskeletal tubulin genes TUBA4A and TUBB1 associated with die-back of degenerative central nervous system disorders, including Alzheimer's disease, PD and amyotrophic lateral sclerosis (ALS), using a transcriptomic diagnostic test on white blood cells, based on mRNA expression, called GENIE (Genomic expression: inflammation explained). The use of transcriptomics provides a better understanding of the genomic underpinnings mediating disease expression and the relationship between gene-environment interactions in neurodegenerative disorders.


This paper reports our findings of a unique transcriptomic fingerprint, including tubulin genes, densely found in symptomatic PD patients and much younger patients with fewer symptoms. The grouping is represented by clusterin (CLU) and a panel of coagulation (COAG) genes, called "Triple Positives," consistently found in a subset of Chronic Inflammatory Response Syndrome (CIRS) patients, independent of age but invariantly linked to patients with at least three upregulated COAG genes. Treatment with a published CIRS protocol in a small study corrects many symptoms and Triple Positives, regulating normal gene expression.


This fingerprint supports reports of similar transcriptomics in the PD literature but is the first to demonstrate successful resolution of differentially expressed genes in PD using commercially available medications. Finding Triple Positives in CIRS patients younger than 50, in the absence of toxic compounds like MPTP and instead initiated by exposure to WDB, raises the possibility of neuroprotection from PD if intervention were initiated before neurodegenerative changes are underway. While many putative causes of PD have been explored, a genomically mediated model of disease initiation and expression has emerged supporting a potential paradigm shift regarding PD, . Our work offers a unified framework of environment-gene interaction in the PD population connected to contaminated indoor living spaces, which we term CIRS-PD.

Article Details

How to Cite
SHOEMAKER, R et al. A Transcriptomic Fingerprint for Parkinson's Disease Found in Patients with Chronic Inflammatory Response Syndrome: Implications for Diagnosis, Treatment and Prevention. Medical Research Archives, [S.l.], v. 12, n. 9, sep. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5788>. Date accessed: 03 oct. 2024. doi: https://doi.org/10.18103/mra.v12i9.5788.
Section
Research Articles

References

1. Elbaz A, Carcaillon L, Kab S, et al. Epidemiology of Parkinson's disease. Rev Neurol 2016; 172: 14-26.
2. Karaaslan Z, Ozlem T. Sanli E, et al. Inflammation and regulatory T cell genes are differentially expressed in peripheral blood mononuclear cells of Parkinson's disease patients. Scientific Reports 2021; 11: 2316.
3. Shoemaker R, Heyman A, Lark D. TUBB1, TUBA4A and MAPK as indicators of die-back degenerative central nervous system disease in patients sickened by specific exposure to the interior environment of water-damaged buildings. Medical Research Archives 2023; 11: 1-11
4. Shoemaker R, McMahon S, Ryan J, et al. Intranasal VIP restores volume in multiple grey matter nuclei in patients with CIRS. Int Med Rev 2017; 3: 1-14.
5. Kurvits L, Lattekivi F, Reimann E, et al. Transcriptomic profiles in Parkinson's disease. Experimental Biology and Medicine 2021; 246: 284-295.
6. Shen J, Chang X, Wang-Lun C, et al. Identification of Parkinson's disease-related pathways and potential risk factors. Journal of International Medical Research 2020; 48: 1-13
7. Tan E, Chao Y, West A, et al. Parkinson's disease and the immune system association, mechanisms and therapeutics. Nature Rev Neurology 2020; 16: 303-318.
8. Hoehn M and Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-42
9. www.movedisorder.com accessed 7/31/24.
10. GBD 2016 Parkinson's Disease Collaborators. Global, regional and national burden of Parkinson's Disease, 1990-2016. Lancet Neurology 2018; 17; 939-953.
11. Shoemaker R, Johnson K, Jim L, Berry Y, Dooley M, Ryan J, McMahon S. Diagnostic process for CIRS: A consensus statement report of Surviving Mold. Int Med Rev,2018; 4:1-46.
12. Cortes-Cantell M, Zamolodchikov D. Ahn H, et al. Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimer's Dis 2012; 32: 599-608.
13. Zamolodchikov D, Strickland S. A possible new role for AB in vascular and inflammatory dysfunction in Alzheimer's disease. Thromb Res 2016; Suppl 2: S59-61.
14. Ahn H, Chen Z, Zamolodchikov D, et al. Interactions of B-amyloid peptide with fibrinogen and coagulation factor XII may contribute to Alzheimer's disease. Curr Opin Hematol 2017; 25: 427-431
15. Melchor J, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005; 93: 655-660.
16. Singh P, Simoes-Pires E, Chen Z, et al. Lecanemab blocks the effects of the AB/fibrinogen complex on blood clots and synapse toxicity in organotypic culture. PNAS 2024; 121: 17: e2314450121.
17. Norris E, Strickland S. Fibrinogen in the nervous system: Glia Beware. Neuron 2017; 96: 951-953.
18. Singh P, Badimon A, Chen Z, et.al. The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy. Res Pract Thromb Haemost 2021; 5: e12504.
19. Tataryn N, Singh V, Dyke J, et al. Vascular endothelial growth factor associated dissimilar cerebrovascular phenotypes in two different mouse models of Alzheimer's disease. Neurobiol Aging 2021; 107: 96-108.
20. Ahn H, Baker S, Norris E, Strickland S. Inflaming the Brain. Neuron 2019; 101: 991-993.
21. Chen Z, Singh P, Calvano M, et.al. A mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer's disease. PNAS 2023; 36: e2309389120.
22. Baker S, Strickland S. A critical role for plasminogen in inflammation. J. Exp. Med. 2020; 217: 4: e20191865.
23. Strickland S. Blood will out: vascular contributions to Alzheimer's disease. Clin Invest 2018; 128: 556-563.
24. Shihabuddin L, Brundin P, Greenamyre J, et.al. New frontiers in Parkinson's disease: from genetics to clinic. J Neurosci 2018; 9375-9382.
25. Do C, Tung J, Elizabeth D, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet 2011; 7: e1002141.
26. Hernandez D, Nalls M, Ylikotila P, et al. Genome wide assessment of young onset Parkinson's disease from Finland. PLoS One 2012; 7: e41859.
27. Ritchie M, Phipson B, Wu D, et al. LIMMA powers differential expression analyses for RNA-sequencing and microarray studies. Nuclei Acids Res 2015; 43: e47.
28. Alam Q, Alam M, Mushtaq G, et al. Inflammatory process in Alzheimer and Parkinson's disease: significant role of cytokines. Curr Pharm Des 2015; 22: 541-548.
29. Mutez E, Nkiliza A, Belarbi K, et al. Involvement of immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease. Neurobiol Dis 2014; 63: 165-170.
30. Obeso, J.A., Stamelou, M., Goetz, C.G., Poewe, W. & Land, AE Past, present and future of Parkinson's disease: a special essay on the 200th anniversary of the shaking palsy. Mov. Disord.201 7; 32, 1264-131).
31. Kalia, LV & Lang, A.E. Parkinson's disease. Lancet 2015; 386, 896-912.
32. Johnson M, Stecher B, Labrie V, et al. Triggers, facilitators and aggravators: redefining Parkinson’s disease pathogenesis. Trends in Neurosci,2019; 42: 4-13.
33. Chao, Y., Wong, S. C. & Tan E. K. Evidence of inflammatory system involvement in Parkinson's disease. Biomed. Res. Int. 2014; 308654.
34. Holmans, P., Moskvina, V., Jones, L., Sharma, M. & Vedernikov, A. A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum. Mol. Genet. 2013; 22: 1039-1079.
35. Gruden, M.A., Yanamandra, K., Kucheryanu, V.G, Bocharova, O. R. & Sherstnev, V. V. Correlation between protective immunity to a-synuclein aggregates, oxidative stress and inflammation. Neuroimmunomodulation 2012; 19: 334-342.
36. Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009; 8: 382-397.
37. Duffy M, Collier T, Patterson J. Lewy body-like alpha synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J. Neuroinflammation 2018 15; 129.
38. Lin, C. H., Chen, C.C., Chiang, H. L., Liou, J. M. & Chang, C. M. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease. J. Neuroinflammation 2019; 16, 129).
39. Mogi, M., Harada, M., Narabayashi, H., Inagaki, H. & Minami, M. Interleukin (IL)-1B, IL-2, IF-4, IL-6 and transforming growth factor a levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 1996; 211: 13-16.
40. Wang, W. et al. Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein a-synuclein. Proc. Natl Acad. Sci USA 2016; 113: 9587-9592.
41. Kempuraj, D., Selvakumar, G.P., Zaheer, S., Thangavel, R. & Ahmed, M.E. Cross-talk between glia, neurons and mast cells in neuroinflammation associated with Parkinson's disease. J. Neuroimmune Pharmacol. 2018; 13: 100-112.
42. Stefanis, L. et al. How is alpha-synuclein cleared from the cell? J. Neurochem. 2019; 150: 577-590.
43. Ahmed, I., Tamouza, R., Delord, M., Krishnamoorthy, R. & Tzourio, C. Association between Parkinson's disease and the HLA-DRB1 locus. Mov. Disord. 2012; 27: 1104-1110.
44. Kustrimovic, N. et al. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. J. Neuroinflammation 2018; 15: 205.
45. McGeer, P. L., Itagaki, S. & McGeer, E. G. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 1988; 76:: 550-557.
46. Ham, J. H., Yi, H., Sunwoo, M. K., Hong, J. Y. & Sohn, Y. H. Cerebral microbleeds in patients with Parkinson's disease. J. Neurol. 2014; 261: 1628-1635.
47. Liu, Z., Huang, Y., Cao, B. B., Qiu, Y. H. & Peng, Y. P. Th17 cells induce dopaminergic neuronal death via LFA-1/lCAM-1 interaction in a mouse model of Parkinson's disease. Mol. Neurobiol.2017; 54: 7762-7776
48. Mogi, M., Harada, M., Narabayashi, H., H., Inagaki, H. & Minami, M. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 1996; 221: 13-16.